CONFERENCE PROGRAM

Saturday, May 18

6:30 p.m.–7:30 p.m.  WELCOME AND OPENING KEYNOTE SESSION
Aspen Ballroom

Welcome Remarks
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

The epigenetics of cancer
Peter A. Jones, Van Andel Research Institute, Grand Rapids, MI

7:30 p.m.–9:30 p.m.  WELCOME RECEPTION
Colorado Ballroom

Sunday, May 19

7:00 a.m.–8:00 a.m.  CONTINENTAL BREAKFAST
Colorado Ballroom

8:00 a.m.–10:00 a.m.  PLENARY SESSION 1: MOLECULAR PATHOLOGY: OMICS, SUBTYPES, BIOMARKERS
Aspen Ballroom

Session Chair: Donna E. Hansel, Oregon Health & Science University, Portland, OR

Molecular subtypes and liquid biopsies for predicting outcome in bladder cancer
Lars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark

Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity
David J. McConkey, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD

Molecular alterations in variant morphology
Donna E. Hansel

The shifting landscape of genomics: Impact on clinical decision making
Seth P. Lerner, Baylor College of Medicine, Houston, TX

Novel role of ketone body metabolism in acquired gemcitabine resistance*
Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, CA

10:00 a.m.–10:30 a.m.  BREAK
Aspen Ballroom Foyer

*Short talk from proffered abstract.
10:30 a.m.–12:30 p.m.  PLENARY SESSION 2 AND PANEL DISCUSSION: URINE MOLECULAR DIAGNOSIS
Aspen Ballroom

Session Chair: Tahlita C.M. Zuiverloon, University of Colorado Denver, Aurora, CO

A urine assay to triage patients with hematuria for cystoscopy
Joep de Jong, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

Potential benefits of and obstacles to use of urine-based tumor markers
Yair Lotan, UT Southwestern Medical Center, Dallas, TX

Incorporating proteomics in bladder cancer molecular diagnosis
Antonia Vlahou, Biomedical Research Foundation Academy of Athens, Athens, Greece

Profiling intratumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology*
Andries Zijlstra, Vanderbilt University Medical Center, Nashville, TN

Panel discussion
Donna E. Hansel, Yair Lotan, Antonia Vlahou, Joep de Jong

12:30 p.m.–3:00 p.m.  POSTER SESSION A / LUNCH
Colorado Ballroom

3:00 p.m.–5:00 p.m.  PLENARY SESSION 3: DRIVERS OF DISEASE: STEM CELLS, MOLECULAR PATHWAYS, TUMOR MICROENVIRONMENT
Aspen Ballroom

Session Chair: William Y. Kim, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Collagen microenvironment in the modulation of local invasion and distal metastasis
Keith S. Chan, Baylor College of Medicine, Houston, TX

Developing rational combination therapy with checkpoint inhibitors
Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

Chemotherapy remodels the bladder cancer immune microenvironment
William Y. Kim

Can immunologic biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC?*
Melinda Lillesand, Stavanger University Hospital, Stavanger, Norway

Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes*
Markus Eckstein, University Hospital Erlangen, Erlangen, Germany

*Short talk from proffered abstract.
CONFERENCE PROGRAM

Monday, May 20

7:00 a.m.–8:00 a.m. CONTINENTAL BREAKFAST
Colorado Ballroom

8:00 a.m.–10:00 a.m. PLENARY SESSION 4: BASIC AND TRANSLATIONAL IMMUNO-ONCOLOGY
Aspen Ballroom
Session Chair: Charles G. Drake, Columbia University Medical Center, New York, NY
Basic immunologic mechanisms of PD-1/PD-L1 blockade
Gordon Freeman, Dana-Farber Cancer Institute, Boston, MA
NK cell activation and inactivation in the tumor microenvironment: Potential for mobilizing NK cells for cancer therapy
David H. Raulet, University of California Berkeley, Berkeley, CA
Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma
Matthew Albert, insitro, South San Francisco, CA
(not eligible for CME)
Novel immunotherapy combinations for bladder cancer
Charles G. Drake

10:00 a.m.–10:30 a.m. BREAK
Aspen Ballroom Foyer

10:30 a.m.–12:45 p.m. PLENARY SESSION 5: MODELS FOR DISCOVERY
Aspen Ballroom
Session Chair: Dan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA
Genetic mouse models and organoids: Synergy for functional genomics of bladder cancer genes
Francisco X. Real, Spanish National Cancer Center (CNIO), Madrid, Spain
Patient-derived organoid models of bladder cancer
Michael M. Shen, Columbia University College of Physicians and Surgeons, New York, NY
Genetic modeling of bladder cancer in the post-genome era
Xue-Ru Wu, NYU School of Medicine, New York, NY
PDX and genetic mouse models for deciphering signaling pathways in bladder cancer
François R. Radvanyi, Institut Curie, Paris, France
Similarities in molecular subtypes and subtype immune patterns between naturally occurring canine and human invasive bladder cancer*
Deborah Knapp, Purdue University, West Lafayette, IN
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy*
Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, WA

*Short talk from proffered abstract.
12:45 p.m.–3:30 p.m.  FREE TIME / LUNCH ON OWN

3:30 p.m.–5:00 p.m.  PLENARY SESSION 6: MANAGEMENT OF NONINVASIVE DISEASE
Aspen Ballroom

Session Chair: Peter C. Black, University of British Columbia, Vancouver, BC, Canada
Intravesical versus systemic therapy: Win, lose, or draw—the future is now for multidisciplinary NMIBC drug development
Noah M. Hahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Intravesical gene therapy for NMIBC
Colin P.N. Dinney, The University of Texas MD Anderson Center, Houston, TX

Realizing the potential of targeted therapy in NMIBC
Peter C. Black

5:00 p.m.–7:30 p.m.  POSTER SESSION B / RECEPTION
Colorado Ballroom

Tuesday, May 21

7:00 a.m.–8:00 a.m.  CONTINENTAL BREAKFAST
Colorado Ballroom

8:00 a.m.–10:00 a.m.  PLENARY SESSION 7: NEOADJUVANT AND BLADDER-SPARING APPROACHES TO INVASIVE DISEASE
Aspen Ballroom

Session Chair: Jason A. Efstathiou, Massachusetts General Hospital, Boston, MA
Recent clinical advances in trimodality therapy including combining immunotherapy with chemoradiation
Jason A. Efstathiou

Predictive biomarkers of response to neoadjuvant therapy
Kent W. Mouw, Dana-Farber Cancer Institute, Boston, MA

Molecular biomarkers of chemoradiation response in bladder preservation therapy
David T. Miyamoto, Massachusetts General Hospital, Boston, MA

Targeting hypoxia and personalizing chemoradiation
Catharine West, University of Manchester, Manchester, United Kingdom

Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC)*
Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*Short talk from proffered abstract.
CONFERENCE PROGRAM

10:00 a.m.–10:20 a.m. BREAK
Aspen Ballroom Foyer

10:20 a.m.–12:00 p.m. PLENARY SESSION 8: MANAGEMENT OF METASTATIC DISEASE
Aspen Ballroom

Session Chair: Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY

New agents in metastatic urothelial carcinoma
Andrea B. Apolo, National Cancer Institute, Bethesda, MD

Shaping the future of treatment for metastatic disease: Current standards of care and the clinical trial landscape
Dean F. Bajorin

The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA*
Gillian Vandekerkhove, Vancouver Prostate Centre, Vancouver, BC, Canada

Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab*
Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, MD

12:00 p.m. CLOSING REMARKS / DISCUSSION
Aspen Ballroom

*Short talk from proffered abstract.